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ABSTRACT 
INTRODUCTION Autosomal dominant polycystic kidney disease (ADPKD) is the most common renal hereditary 
disorder. Several authors have attempted to identify a kidney damage marker for predicting the prognosis and the 
effectiveness of therapy in ADPKD. The aim of this study was to identify and quantify in ADPKD, through a novel MR 
protocol with 3 Tesla (MRI 3Tesla), the presence of parenchymal fibrotic tissue at early stage of disease, able to 
correlate the glomerular filtrate and to predict the loss of the function renal. 
MATERIAL AND METHODS 15 ADPKD patients undergone to renal MRI 3Tesla at T0 and revaluated after follow 
up (T1) of 5 years. We have evaluated renal function, plasma aldosterone concentration (PAC), insulin resistance and 
surrogate markers of atherosclerosis (carotid intima media thickness (IMT), ankle/brachial index (ABI) and left 
ventricular mass index (LVMI). 
RESULTS Our study showed a significant negative correlation between total kidney volume and estimated glomerular 
filtration rate (eGFR) during observational observation (p<0.02). Moreover, we showed a negative correlation between 
eGFR with Total Fibrotic Volume (TFV) (p<0.04) and Total Perfusion Volume/Total kidney Volume(<0.02).  
Moreover TFV was correlated positively with PAC (p<0.05), insulin values (p<0.05), ABI (p <0.05) and 
LVMI(p<0.01). 
CONCLUSIONS The MRI 3Tesla, despite the high costs, could be considered an useful and non-invasive method in 
the evaluation of fibrotic tissue and progression of the disease in ADPKD patients. Further clinical trials on larger group 
are due to confirm the results of this pilot study, suggesting that MRI 3Tesla can be useful to evaluate the effectiveness 
of new therapeutic strategies. 
 
Keywords: Autosomal dominant polycystic kidney disease, total volume fibrotic, plasma aldosterone, subclinical 
atherosclerosis parameters. 
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Autosomal dominant polycystic kidney disease (ADPKD) is most common kidney genetic disease with a prevalence 
from 1:400 to 1:1000 live births, characterized by multiple and bilateral cystic dilatation of the renal tubules that lead to 
an enlargement in the total kidney volume (TKV) and to kidney failure. ADPKD can arise from mutations in either the 
PKD1 gene (cr. 16p13.3), which encodes the protein polycystin 1 or the PKD2 gene (cr. 4p13q23), encoding polycystin 
2 (1). PKD1-associated disease presents a more severe prognosis and an earlier progression to end-stage renal disease 
(ESRD) respect to PKD2, with the mean age of 54 years for PKD1 and 74 years for PKD2 to developing renal 
insufficiency (2). The renal function remain normal for many years with an inexorably rapid decline in the final stage of 
disease in ADPKD patients. Caroli et al (3) showed that in an advanced stage of disease, the main component of the 
damage is the tubule interstitial fibrosis. Fibroblasts and collagen fibers build up in the parenchyma with different 
distribution: collagen type I and III are located in the interstice, while collagen type IV is in the basement membrane. 
Interstitial fibrosis could come from cortical ischemia produced by the vascular lesions and luminal narrowing (4-5). 
The tubule-interstitial damage could also be caused by cytokines and chemokines released from inflammatory cells 
present in kidney tissue; this is also supported by large infiltrated of macrophages in the fibrotic tissue. Another 
important role in the pro-inflammatory factors secretion could be played by aldosterone. High levels of aldosterone 
enhance the expression of osteopontina, MCP-1, IL-6 and IL-1β. Aldosterone has also direct proliferative and 
fibrogenetic activity respectively mediated by its functions on MAPK in the nucleus and its ability to increase TGFβ 
production (6-7). All these mechanisms are very important because currently, we have the need of novel biomarkers of 
functional loss and indexes of disease progression, especially for testing new therapeutic strategies. The evaluation of 
fibrotic progression in ADPKD kidneys, estimated with specific Magnetic Resonance Imaging (MRI) sequences, could 
be a promising predictive factor for the evaluation of the onset of renal damage (8).  
AIM OF THE STUDY  
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The aim of study was to identify and quantify the parenchymal fibrotic tissue, possible marker of kidney damage at an 
early stage of the disease with MRI, correlating with the estimated glomerular filtration rate (eGFR), predicting the loss 
of kidney function. 
MATERIALS AND METHODS 
The study protocol was approved by the Local Clinical Research Ethics Committee with protocol number 3169/15. The 
study conforms to the principles outlined in the Declaration of Helsinki and we obtained a written consent by each 
patient enrolled. 
Study design and subjects 
We performed a prospective longitudinal study on ADPKD patients at the University Hospital “Policlinico Umberto I” 
of Rome, Sapienza University of Rome, Italy. Patients were consecutively enrolled from July 2010 and June 2016. 
Clinical, laboratory, instrumental parameters were evaluated at baseline (T0) and at 5 years (T1). 
Patients 
15 ADPKD patients (4 males and 11 females, mean age 39.0±9.2 years) were evaluated at time of diagnosis (T0) and 
after follow-up (T1). The eGFR was evaluated according to the modification of diet in renal disease formula (9), CKD-
Epidemiology and creatinine clearance in a 24-hour urine. We enrolled patients both normotensive and hypertensive. 
The state of arterial hypertension was defined by use of hypotensive drugs (angiotensin converting enzyme (ACEIs), 
Angiotensin II receptor blockers (ARBs), beta-blockers, calcium antagonists, alpha-lytic and / or diuretics) or by the 
presence of a pressure higher than 140/80 mm Hg in three consecutive measurements. Patients on antihypertensive 
treatment with ACEIs and/or ARBs, beta-blockers and alpha-lytic have been subjected to a wash-out period of 15 days 
by replacing the hypotensive therapy with clonidine.  
Inclusion criteria 
Patients aged >18 years with diagnosis of ADPKD, defined according to the Pei's criteria (10).  
Exclusion criteria 
We excluded patients having kidney surgery, or submitted to the cyst drainage procedures, or patients with other 
diseases that can potentially affect kidney function, patients with metal clip carriers, or patients in pregnant or nursing 
patients. Moreover, patients that refused to give consent and patients with missing data were also excluded. 
Laboratory measurements 
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Blood was drawn in the morning after an overnight fasting of at least 12 h. In all patients, the levels of fasting plasma 
glucose (mg/dL), insulin (µU/mL), total serum cholesterol (mg/dL), triglycerides (mg/dL), high-density lipoprotein 
(mg/dL), creatinine (mg/dL), serum nitrogen (mg/dL), serum uric acid (mg/dL), calcium (mg/dL), phosphorus (mg/dL), 
serum electrolytes (mEq/L), C-reactive protein (μg/L), homocysteine (µmol/L) were measured using standard 
automated techniques. Low-density lipoprotein-cholesterol was calculated using the Friedewald equation: low-density 
lipoprotein (mg/dL) = total cholesterol−high-density lipoprotein− (triglycerides/5). Parathyroid Hormone was measured 
using a two-site assay that measures “intact” hormone (iPTH) (pg/mL) and 25-hydroxyvitamin D (25-OH-VitD) 
(ng/mL) was measured by radioimmunoassay. Serum albumin (g/dL) was determined by bromcresol purple method. 
Insulin resistance was assessed using the homeostasis model assessment (HOMA-IR) originally described by Mathew et 
al. (20). Microalbuminuria 24 h (30-300 mg/24h) were carried out. The determination of plasma renin activity (PRA) 
was performed by radioimmunoassay tests using a commercial kit (Ren CTK, Sorin Biomedica). The normal range at 
rest and with normal sodium diet was 0.2 to 2.7 ng/mL/h. The determination of plasma aldosterone concentration (PAC) 
was performed by RIA tests using a commercial kit (Aldosterone Maia Kit, Adaltis Italia S.p.A., Bologna, Italy)(11).  
Blood pressure measurements 
Clinic BP measurements were made 3 times after 10 minutes of rest in a seated position, using a standard automatic 
sphygmomanometer and cuffs adapted to the arm circumference, according to the British Hypertension Society 
guidelines (12). Then, the mean values for systolic blood pressure (SBP) and diastolic BP (DBP) were calculated for all 
participants. The systolic and diastolic BP levels were taken as the points of appearance and disappearance of Korotkoff 
sounds, respectively. Hypertension was defined as SBP ≤ 140 mmHg or DBP ≤ 80 mmHg on repeated measurements.  
We have determined Ankle/Brachial Index (ABI), the measurement of the ratio of the systolic blood pressures in the 
ankle and in the arm (normal values 0.9-1) (13). 
Echocardiography 
All patients underwent transthoracic echocardiography with a commercially available cardiovascular ultrasound system 
(Vivid E9, GE, Horten, Norway). Measurements of cardiac chambers were made according to established criteria (14). 
Left ventricular ejection fraction, by modified biplane Simpson method, and left ventricular mass index (LVMI) were 
estimated. Peak early (E) and late (A) diastolic velocities, deceleration time, left ventricular isovolumic relaxation time, 
and myocardial performance index were obtained using standard Doppler practices. Standard parasternal, apical, and 
subcostal views were used (15).  
Common carotid intima-media thickness assessment (IMT) 
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Right and left carotid ultrasound was blindly performed by an experienced sonographer (S.L.) who was unaware of the 
characteristics of the patients under examination. Participants were studied with the high-resolution B-mode ultrasound 
machine, Toshiba Aplio XV (Toshiba Aplio XV, Toshiba American Medical Systems, Inc., Tustin, CA, USA) equipped 
with a 5- to 12-MHz linear transducer with a 0.01-mm resolution, following a standardized vascular protocol. IMT was 
measured at three points on the far walls of both left and right distal common carotid arteries, carotid bulb, and the 
proximal portion of the internal carotid arteries (16). The mean IMT was computed as the average IMT on both sides. 
The value of IMT was considered normal when between 0.55 and 0.9 mm (17). 
Magnetic Resonance Imaging (MRI) 
All patients were subjected to a novel MRI protocol of advanced imaging with magnet 3T (Discovery MR 750, 3T, GE 
Healthcare) after positioning of the surface coil 32 channels. The acquisition protocol included morphological 
sequences, single shot T2-weighted (SSFS)(TR 850 ms, TE 105 ms; Flip Angle 90°; FoV 320x320; Matrix 320x224) 
acquired on axial, sagittal and coronal planes and sequences Gradient Echo (GRE ) T1-weighted (TR 5 ms; TE 1ms; 
Flip Angle 15°; FoV 420x420; 288x192 matrix). For the evaluation of parenchymal perfusion were used sequences 
ultrafast GRE T1-weighted, acquired in the coronal plane (TR 2 mS; TE 1 mS; Flip Angle 13°; Thickness 200 mm; 
FoV 300x300 mm, matrix 192x138) during administration dynamic of i.v. contrast (Gadobutrol 1 mmol/ml, Gadovist, 
Bayern) using a perfusion technique, with high temporal resolution of 4 seconds, for a total duration of about 8 minutes. 
The departure of the dynamic sequence was made to coincide with the start of the administration of contrast material 
i.v. (18). The evaluation of Total Perfusion Volume (TPV) and Total Fibrotic Volume (TFV) results from Perfusional 
MRI after a qualitative and quantitative approach. Each parameter resulted from a post-processed slice by slice renal 
segmentation rispectively in early arterial phase (1st minute of perfusion) and late perfusional fase (8th minute of 
perfusion). Segmentation was guided using colorimetric maps. After segmentation, software Workstation vers. 4.6 was 
used for 3D volume rendering reconstrucion, which resulted in semiquantitative estimation of parenchymal perfonded 
tissue and fibrotical areas. These perfusional parameters give indication of functional parenchimal areas. Perfusional 
volume indicates kidney’s areas where blood flow is preserved, which is an indirect sign of normal functional 
parenchyma. Fibrotical areas indicate parenchymal areas which underwent to fibrotical substitution and consequent loss 
of function. 
Image analysis 
Morphological Assessment 
In the morphological images HASTE T2 and T1-weighted 3D GRE, the following parameters were evaluated: kidney 
size on 3 floors of acquisition (axial sagittal and coronal), cortical thickness, cortico-medullary differentiation, volume 
of cysts. In the 3D T1 weighted GRE sequences, the morphological characteristics and the signal intensity, relating to 
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the presence or absence of a high protein content have been evaluated, allowing the identification of hemorrhagic cyst 
content, infected cysts and degenerate cysts. 
Qualitative and Quantitative Assessment  
The perfusion technique was evaluated with both qualitative and quantitative approach. In the first case, two types of 
colorimetric maps were obtained, reconstructed both at an early stage that at a late stage. The colorimetric map 
elaborated in the early stage reflects an enhancement of arterial type, derived from the analysis of the early stages, 
which identify the normally perfused renal parenchyma, and which may be defined as "functional." The colorimetric 
map developed in the late phase, shows the strengthening of focal renal parenchymal areas, that may identify areas of 
parenchymal fibrosis. The colorimetric maps also allow a 3D three-dimensional reconstruction of the kidney (Volume 
Rendering achieved by GE, Workstation software vers. 4.6) to highlight the renal parenchyma perfused, called 
"perfusion volume". This result was obtained by using the colorimetric map derived from early-stage acquisitions that 
corresponds to approximately 35 seconds after the beginning of injection of the contrast medium and the colorimetric 
maps obtained in the late phase, which corresponds to about 8 minutes from the start of injection of the contrast agent; 
the latter made it is possible to evaluate the estimate of parenchymal fibrosis defined as "fibrotic volume" (19). 
Statistical analysis 
Data management and analysis were performed using IBM® SPSS® Statistics 22.0 for Windows® software (IBM 
Corporation, New Orchard Road Armonk, New York, United States). The normality of variables was tested using the 
Shapiro-Wilk method for normal distributions. All continuous variables were expressed as mean ± standard deviation, 
categorical variables were expressed as number (percentage). Spearman's correlation was used to determine in bivariate 
correlation the relationship and the strength of association between the variables. A probability value of p <0.05 was 
considered to be statistically significant. 
RESULTS 
The clinical charasterics of ADPKD patients are shown in Table 1. The mean follow-up was 52.80 ± 17.95 months. As 
awaited, renal function has been gradually reduced in all patients. The slope of eGFR varies from -0.06 to -0.56 
mL/mi/1.73 m2/month. The assessment of renal diameters in coronal, axial and sagittal allowed the calculation of the 
height-adjusted total kidney volume (htTKV) (Table 1). MRI showed by colorimetric maps obtained both in early and 
late phase of the parenchymal fibrosis share, defined as "fibrotic volume" (Figure 1) and proportion of perfused 
parenchyma, defined as "perfusion" volume (Figure 2), it was 330.57 ± 266.10 and 392.40 ± 402.83 cm3, respectively 
(Table 1). The mean value of htTKV was result 840.08 ± 816.72 cm3. The mean ratio between the total perfusion 
volume and total kidney volume, expressed as a percentage (TPV/TKV%) varies from 22% to 107% at T0 and from 
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12% to 91% at follow up (T1). The analysis of correlations between the TKV and eGFR at follow up (T1), showed a 
statistically significant negative correlation between the two parameters (r =-0.59, p=0.02), while the same parameters 
evaluated at T0 showed no correlation (Figure 3). We found a trend of correlation between the TPV and eGFR at T1 
(r=-12.48, p=0.06). Moreover, we found a negative correlation between eGFR and TFV (r=-0.61, p=0.04), and eGFR 
with TPV/TKV % (r=-0.59, p=0.02) at T1 (Figure 4). No significative correlations were found between TKV (r=0.37, 
p=0.16) and TPV/TKV % (r=-0.16, p =0.56) with progressive reduction of eGFR. Moreover, in this study PAC was 
correlated positively with the TFV (r=0.50, p=0.05). Subdividing patients in according to age (21-34 and 35-51 years), 
aldosterone showed a significant correlation with the higher age class (r = 0.88, p <0.003), and not in lower age (r=-
0.03, p=0.93). Our study also showed a positive correlation between the TFV with insulin values (r=0:49, p<0.05), ABI 
index (r = 0.51, p<0.05) and LVMI (r=0.63, p<0.01), but no significant correlation with IMT. PRA was in the normal 
range in all patients (data not shown). 
DISCUSSION 
In the present study, we investigated a novel MRI protocol, using advanced imaging with 3Tesla high field magnet, that 
through colorimetric Maps in the early and late phase, with 3D three-dimensional reconstruction, identifies areas of 
parenchyma perfused called “perfusion volume”, and areas of renal fibrosis defined “fibrotic volume”. Total Fibrotic 
Volume is a noncystic area of the polycystic kidney, characterized by peritubular interstitial fibrosis, tubular dilation, 
atrophy and vascular sclerosis. Total Perfusion Volume represents the noncystic fraction of the polycystic kidney with a 
normal perfusion and tissue architecture. It is known that eGFR is a late marker of kidney damage in ADPKD, while the 
presence of fibrosis was documented in an early phase of disease, with preserved renal function and TKV slightly 
increased. The sequential evaluation of TKV and the cystic volume has been adopted in recent years in several clinical 
trials as a measure of outcome, but these showed no linear correlation with worsening renal function, if not in the late 
stages of the disease. In fact, the Consortium for Radiologic Imaging in Polycystic Kidney Disease cohort (CRISP) 
study, showed that in ADPKD patients Magnetic resonance-based htTKV over 600 ml/m predicts the development of 
CKD Stage 3 within 8 years, and that TKV and cyst volume increase exponentially with age, but causal relationship 
between kidney or cyst volume increase and the progression to ESRD has not been completely demonstrated. In our 
study, TKV was negatively correlated with eGFR at T1, in according with CRISP study (8), while the same parameters 
evaluated at T0 didn’t showed any correlation, confirming that TKV and eGFR could not be correlated in the early 
stages of disease. Moreover, we showed a negative correlation between eGFR and TFV, and a positive correlation 
between eGFR and TPV/TKV % at T1, suggesting these as possible new markers that could be used to assess disease 
progression and efficacy to therapy. Instead, TPV showed a negative correlation, albeit without statistical significance, 
with eGFR at T1, perhaps this may also be due to the low number of the sample examined. Caroli et al.(3) have 
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characterized extracystic tissue on contrast-enhanced computed tomography (CT), subdividing extracystic tissue into 
two separate components, fully enhanced and hypoenhanced parenchyma tissue, called "intermediate", and they showed 
that intermediate tissue significantly correlated with eGFR. Moreover in our study we showed that PAC was correlated 
positively with the TFV, and subdividing patients into age groups (21-34 and 35-51 years), PAC showed a significant 
correlation with the higher age class, resulting however not correlated in patients with a lower age. The results obtained 
could confirm an involvement of the aldosterone in the development of renal fibrosis, especially in advanced stages, the 
result of a mechanism which starts already in the initial stage of the disease, and that gradually leads to irreversible loss 
of renal parenchyma. On the contrary, the PRA was normal in all patients. Valvo and Other authors (20) have suggested 
that the suppression of the renin-angiotensin-aldosterone and low renin values in ADPKD patients could be due to an 
increased plasma volume. The production of aldosterone, has been demonstrated also in extra adrenal tissue and appears 
to be only partially influenced by the plasma levels of angiotensin II (21). It would be connected to the production of 
extracellular matrix and could, therefore, have a pathophysiological role in the genesis and progression of chronic 
kidney damage. In addition, normal PRA, does not exclude the presence of a strongly activated intrarenal RAAS, 
demonstrated in ADPKD patients (22), with a local overproduction of angiotensin II and aldosterone, and consequent 
hemodynamic and chronic inflammatory tissue action (7, 23). The hyperproduction of aldosterone determines arteriolar 
vasoconstriction, production of cytokines and adhesion molecules with consequent recall of inflammation cells, 
chemotaxis, activation of macrophages and growth of fibroblasts (5). It is able, moreover, to stimulate coagulation, 
through the increase plasminogen activator inhibitor type I, the activation of platelets and the increase of their 
aggregation at the level of bleeding sites. Increased levels of aldosterone and angiotensin II could lead to systemic 
fibrosis, mitogenesis and stimulate the formation of cysts (6). Many studies support the evidence of aldosterone role in 
determining a cardiovascular damage, regardless of angiotensin II and the blood pressure (5-6,11). Indeed the hormone 
could have a fibrotic effect on vascular smooth muscle cells, endothelial cells, cardiomyocytes and renal tissue (24). 
Our results showed that TFV, was correlated positively also with insulin values, ABI index and LVMI. Currently, the 
link between the function of polycystins and insulin value, is still little known, although recently Mao et al. (25) have 
shown that polycystins can regulate the secretion of insulin, being expressed also in the beta cells of pancreatic islet. 
ABI is a simple, non-expensive and non-invasive marker of atherosclerosis, in fact had a high specificity to predict 
future cardiovascular outcomes. Price et al. (13) showed that the combination of IMT and ABI, could have an additive 
effect for predicting CVD, also if in our study only ABI and not IMT resulted correlate with TFV. However, Tokiwa et 
al. (26) showed that in ADPKD patients with preserved renal function, ABI found no significant relationship with 
disease progression, while in our study ABI was significantly correlate with TFV. Currently, we have the need of novel 
biomarkers of functional loss, indexes of disease progression, especially to monitor the effectiveness of therapy. In fact 
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the relationship between eGFR and TKV is stronger during the later stages of disease and total cyst and kidney volume, 
have been often utilized as outcome measures in clinical trials, but Caroli et al. (3) showed that intermediate volume, as 
determined by CT, comparing with gold standard (three ADPKD patients underwent bilateral nephrectomy), mainly 
constituted by tubule interstitial fibrosis, would be considered a better candidate marker for monitoring disease 
progression and, as outcome measures in ADPKD patients. Renal biopsy could represent the gold standard procedure 
but it could be negative and harmful, with possibility to aggravate renal function, especially considering the high rates 
of complications following kidney biopsy. Already in 1960 Landmark et al. showed that renal fibrosis is the best 
histological correlate of the progression of renal damage and long-term prognosis. The decline in renal function in 
ADPKD patients remain underhand for years, as a consequence of increased GFR by surviving nephrons. The 
compression of expanding cysts on parenchymal tissue and the stretching of renal microvessels cause hypoperfusion 
and disruption of the normal tissue architecture leading to progressive renal functional loss. Tubulointerstitial damage, 
is now recognized as an essential element in the decline of renal function. Recent findings that intermediate volume, as 
determined by CT (3), is mainly constituted by interstitial fibrosis, confirm that this imaging parameter could be 
considered as a strong candidate marker for monitoring progression of renal disease, outcomes and therapy efficacy in 
ADPKD patients. 3 Tesla-Diffusion Tensor Imaging without contrast agent is already been used in ADPKD patients by 
Lupica et al (27), with promising results on the evaluation of the fractional anisotropy and apparent diffusion coefficient 
and a good correlation with kidney function tests, but this method without contrast agent, is certainly safer with low 
eGFR (<30 ml/min), but is not able to assess renal fibrous component. Therefore quantification and monitoring of 
fibrotic tissue and its evaluation relative to the preserved parenchyma could allow to stratify ADPKD patients, monitor 
disease progression and evaluate the effects of early treatment strategies when renal function is still preserved and 
patients are considered not at high risk cause to normal eGFR.  
Moreover, renal biopsy could represent the gold standard procedure but it could be negative and harmful, with 
possibility to aggravate renal function, especially considering the high rates of complications following kidney biopsy 
(rupture of cysts, infection and even greater difficulties at the time of transplantation).  
LIMITATION OF THE STUDY 
This study is conducted in small cohort of ADPKD patients, therefore, it should be considered as hypothesis generating 
data, which need to be confirmed by further clinical studies with a larger number of patients. Moreover, the technique 
used to quantify the fibrotic and perfusion volume is "time consuming", and can be considered limited to specialized 
centers with advanced imaging techniques. Therefore, a large clinical trials is necessary to confirm our findings results 
and  that further long-term data on larger population is needed to recommend the procedure in the clinical practice.  
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CONCLUSION 
Our results showed a possible method of advanced imaging, capable of identifying and quantifying the fibrotic and 
perfusion renal volume, already at an early stage of the disease, also with preserved renal function and with a possible 
correlation with the eGFR. Indeed novel MRI protocol of advanced imaging with 3Tesla high field magnet could 
accurately reproduce these changes, even when renal function is still preserved. If our hypothesis is confirmed by larger 
clinical studies, it would be advisable to carry out a study with MRI 3Tesla high field magnet, in the follow up of 
ADPKD patients, to evaluate the progression of the disease and the effectiveness of new therapeutic strategies, despite 
the high costs. 
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ADPKD
Patiens 
Age eGFR
T0 
PAC 
pg/mL 
TFV T1 
cm
3
 
TPV/TKV 
(%)  T0 
TPV/TKV 
(%)  T1 
TKV T0 
cm
3
 
TKV T1 
cm
3
 
htTKV 
T0 
eGFR decline 
mL/min/1.7
3 m2/month 
1 43 67 184.4 327.08 73 68 750 841 422 - 0.17 
2 51 122 189.6 304.94 62 58 629 602 602 - 0.44 
3 40 134 193.6 291.34 107 63 858.8 1045.7 536 - 0.56 
4 21 82 440.3 61 95 91 302.5 307 168 - 0.06 
5 48 82 323.6 422.25 47 61 2035 2380 1197 - 0.47 
6 48 54 201 389.47 40 45 1033 1260 1032 - 0.28 
7 34 73 104 265.32 71 53 559.7 615.4 342 - 0.39 
8 46 92 50 124.74 83 80 519.2 505.6 295 - 0.28 
9 51 66 244.3 1228 22 12 6360 9897 3438 - 0.29 
10 30 100 172 277.74 52 55 818.4 849 508 - 0.12 
11 33 87 141 298.67 56 53 839.6 923.5 486 - 0.10 
12 48 82 148 157.88 65 36 915 1821 495 - 0.56 
13 33 85 102 303.07 36 32 1517 1674 1517 - 0.14 
14 29 112 120 57.17 89 80 409 471 409 - 0.36 
15 30 90 236 450 40 46 1980 2682 1165 - 0.44 
 
Table1: Patient’s characteristics of the study. Abbreviations: ADPKD: Autosomal Dominant Polycystic Kidney 
Disease; TFV, total fibrotic volume; TKV, total kidney volume; htTKV, Height-adjusted total kidney volume; 
TPV/TKV %, ratio between the total kidney volume and total perfusion volume expressed as a percentage; PAC, 
plasma aldosterone concentration.   
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Figure 1. Pattern 3T MRI. Colorimetric map Late Enhancement and 3D reconstruction of the fibrotic volume of the 
right (126.969 cm3) and left kidney (150.771 cm3) in ADPKD patients. Abbreviations: ADPKD: Autosomal 
Dominant Polycystic Kidney Disease; TFV, total fibrotic volume. 
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Figure 2. Pattern 3T MRI. Colorimetric map Late Enhancement and 3D reconstruction of the total perfusion volume of 
the right (257.16 cm3) and left (244. 445 cm3) kidney in ADPKD patients. Abbreviations: ADPKD: Autosomal 
Dominant Polycystic Kidney Disease; TPV, total perfusion volume. 
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Figure 3. Correlation between the TKV and eGFR, at T0 (r = - 0.31, p = 0.24) and at T1 (r = - 0.59, p =0.02) 
in ADPKD patients. Abbreviations: eGFR, estimated Glomerular Filtration rate; TKV, total kidney volume, 
ADPKD: Autosomal Dominant Polycystic Kidney Disease. 
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Figure 4: Correlation between the eGFR and TFV (R = - 0.61,p=004), and between eGFR and (TPV/TKV %) (r= - 
0.59, p =0.02)  at T1 in ADPKD patients. Abbreviations: TFV, total fibrotic volume; eGFR, estimated glomerular 
filtration rate; TPV / TKV%, ratio between the total kidney volume and total perfusion volume expressed as a 
percentage; ADPKD: Autosomal Dominant Polycystic Kidney Disease. 
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